| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10009465 | HBV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS10036839 | HBV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS10062550 | HBV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS30088707 | HIV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS30072166 | HIV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS20065430 | HPV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS20034622 | HPV | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS44022964 | HTLV-1 | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
| TVIS44040355 | HTLV-1 | ENSG00000130707.18 | protein_coding | ASS1 | No | No | 445 | P00966 Q5T6L4 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ASS1 |
|---|---|
| DrugBank ID | DB00125 |
| Drug Name | Arginine |
| Target ID | BE0000671 |
| UniProt ID | P00966 |
| Regulation Type | |
| PubMed IDs | 16787144; 16809898; 17210712; 17354225 |
| Citations | Feun L, Savaraj N: Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006 Jul;15(7):815-22.@@Moradi H, Kwok V, Vaziri ND: Effect of chronic renal failure on arginase and argininosuccinate synthetase expression. Am J Nephrol. 2006;26(3):310-8. Epub 2006 Jun 29.@@Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC: Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007 Jan 1;67(1):309-17.@@Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR: Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer. 2007 Jul 1;121(1):6-11. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | L-alpha-amino acids |
| SMILES | N[C@@H](CCCNC(N)=N)C(O)=O |
| Pathways | Citrullinemia Type I; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Argininemia; Hyperornithinemia with Gyrate Atrophy (HOGA); Canavan Disease; Hypoacetylaspartia; Hyperprolinemia Type II; 3-Phosphoglycerate Dehydrogenase Deficiency; Non-Ketotic Hyperglycinemia; Argininosuccinic Aciduria; L-Arginine:Glycine Amidinotransferase Deficiency; Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Prolidase Deficiency (PD); Glycine and Serine Metabolism; Hyperglycinemia, Non-Ketotic; Dimethylglycine Dehydrogenase Deficiency; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Carbamoyl Phosphate Synthetase Deficiency; Ornithine Aminotransferase Deficiency (OAT Deficiency); Hyperprolinemia Type I; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Aspartate Metabolism; Nitric Oxide Signaling Pathway; Arginine and Proline Metabolism; Ornithine Transcarbamylase Deficiency (OTC Deficiency); Prolinemia Type II; Urea Cycle; Sarcosinemia |
| PharmGKB | PA448478 |
| ChEMBL | CHEMBL1485 |
